SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?

Publisher： Karger

E-ISSN： 2235-3186|137|1|64-67

ISSN： 1660-8151

Source： Nephron, Vol.137, Iss.1, 2017-07, pp. : 64-67

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Urinary Matrix Metalloproteinase Activity in Diabetic Kidney Disease: A Potential Marker of Disease Progression

By  

Nephron Extra, Vol. 2, Iss. 1, 2012-08 ,pp. : 219-232

Karger

Access to resources Recommend Favorite

Integrative Biology of Diabetic Kidney Disease

By  

Kidney Diseases, Vol. 1, Iss. 3, 2015-0 ,pp. : 194-203

Karger

Access to resources Recommend Favorite

The Prevalence of the Risk Factors for Atherosclerosis among Type 2 Diabetic Patients Is Greater in the Progressive Stages of Chronic Kidney Disease

By  

Nephron Extra, Vol. 3, Iss. 1, 2013-07 ,pp. : 66-72

Karger

Access to resources Recommend Favorite

Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease

By  

Nephron, Vol. 129, Iss. 1, 2014-12 ,pp. : 29-33

Karger

Access to resources Recommend Favorite

Diabetic Kidney Disease: Act Now or Pay Later

By  

Kidney and Blood Pressure Research, Vol. 33, Iss. 1, 2010-02 ,pp. : 48-51

Karger

Access to resources Recommend Favorite